Neurochemical dementia diagnostics: assays in CSF and blood

被引：7

作者：

Lewczuk, Piotr ^{[1
]}

Hornegger, Joachim ^{[2
]}

Zimmermann, Ruediger ^{[1
]}

Otto, Markus ^{[3
]}

Wiltfang, Jens ^{[4
]}

Kornhuber, Johannes ^{[1
]}

机构：

[1] Univ Klinikum Erlangen, Dept Psychiat & Psychotherapy, D-91054 Erlangen, Germany

[2] Univ Erlangen Nurnberg, Chair Pattern Recognit, Erlangen, Germany

[3] Univ Ulm, Dept Neurol, D-7900 Ulm, Germany

[4] Univ Duisburg Essen, Dept Psychiat & Psychotherapy, Essen, Germany

来源：

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE | 2008年 / 258卷 / Suppl 5期

关键词：

dementia; cerebrospinal fluid; tau; amyloid; Alzheimer's disease;

D O I：

10.1007/s00406-008-5005-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In this review, current neurochemical dementia diagnostics (NDD) procedures are presented with a focus on biomarkers in the cerebrospinal fluid (CSF) and blood: amyloid P peptides, tau protein, and its phosphorylated form (pTau). CSF analysis is an increasingly important tool for early and differential diagnosis of dementia syndromes. Although lumbar puncture is a mildly invasive procedure with a low incidence of complications, establishing blood assays capable of reliably measuring NDD biomarkers is an aim of several studies worldwide.

引用

页码：44 / 49

页数：6

共 59 条

[1]

Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109

[2] Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample [J].

Andreasen, N ;

Minthon, L ;

Clarberg, A ;

Davidsson, P ;

Gottfries, J ;

Vanmechelen, E ;

Vanderstichele, H ;

Winblad, B ;

Blennow, K .

NEUROLOGY, 1999, 53 (07) :1488-1494

[3] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice [J].

Andreasen, N ;

Minthon, L ;

Davidsson, P ;

Vanmechelen, E ;

Vanderstichele, H ;

Winblad, B ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 2001, 58 (03) :373-379

[4] Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias [J].

Bibl, M. ;

Mollenhauer, B. ;

Lewczuk, P. ;

Esselmann, H. ;

Wolf, S. ;

Trenkwalder, C. ;

Otto, M. ;

Stiens, G. ;

Ruether, E. ;

Kornhuber, J. ;

Wiltfang, J. .

MOLECULAR PSYCHIATRY, 2007, 12 (07) :671-680

[5] Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations [J].

Bibl, M. ;

Mollenhauer, B. ;

Wolf, S. ;

Esselmann, H. ;

Lewczuk, P. ;

Kornhuber, J. ;

Wiltfang, J. .

JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (05) :621-628

[6] CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia [J].

Bibl, M ;

Mollenhauer, B ;

Esselmann, H ;

Lewczuk, P ;

Klafki, HW ;

Sparbier, K ;

Smirnov, A ;

Cepek, L ;

Trenkwalder, C ;

Rüther, E ;

Kornhuber, J ;

Otto, M ;

Wiltfang, J .

BRAIN, 2006, 129 :1177-1187

[7] CSF markers for incipient Alzheimer's disease [J].

Blennow, K ;

Hampel, H .

LANCET NEUROLOGY, 2003, 2 (10) :605-613

[8] CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease [J].

Blennow, K ;

Vanmechelen, E ;

Hampel, H .

MOLECULAR NEUROBIOLOGY, 2001, 24 (1-3) :87-97

[9]

BLENNOW K, 1993, ACTA NEUROL SCAND, V88, P221

[10] Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities [J].

Citron, M ;

Diehl, TS ;

Gordon, G ;

Biere, AL ;

Seubert, P ;

Selkoe, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) :13170-13175

← 1 2 3 4 5 6 →